ESCRT-III is necessary for the integrity of the nuclear envelope in micronuclei but is aberrant at ruptured micronuclear envelopes generating damage

a Examples of the honeycomb and herniated Lamin A and B phenotypes in HeLa cells treated with CHMP7 sRNAi for 48？h. Arrowheads indicate chromatin protruding out the nucleus in herniated cells. b Quantification of Lamin A and B defects in Hela cells treated with the indicated sRNAi (minimum of 300 cells scored per condition). c Examples of CHMP7 foci in HeLa cells treated with VPS4 and NT-control sRNAi for 48？h and associated with LAP2 or Lamin A foci (LAP2 and Lamin A enriched, arrowheads) or associated with Lamin B holes (HeLa M). d Average CHMP7 foci number per nucleus in HeLa (n？=？305), HeLa M (n？=？222), and U2OS (n？=？257) cells treated with VPS4 sRNAi for 48？h. e Quantification of CHMP7 foci in relation to LAP2, Lamin A/C, or Lamin B, in HeLa cells treated with VPS4 sRNAi for 48？h (minimum of 400 foci for each condition). f Deconvolved widefield image of CHMP4B co-localization with CHMP7 at nuclear envelope foci in HeLa cells transfected with VPS4 sRNAi for 48？h (top panel) and CHMP7/CHMP4B distribution in control cells (bottom panel). g Percentage of HeLa cells containing at least one large accumulation of CHMP7 (focus) following VPS4 sRNAi treatment at 24, 48, and 72？h post transfection (minimum of 200 nuclei scored for each condition). h Number of nuclear CHMP foci accumulating in HeLa M cells under the indicated sRNAi treatments. (minimum of 100 nuclei scored for each condition). Averages and SEM are shown (N？=？3). Scale bars represent 10？μ